Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Rhea-AI Summary
Intellia Therapeutics (Nasdaq: NTLA) initiated a rolling BLA submission to the FDA for lonvo-z (formerly NTLA-2002) as a one-time in vivo CRISPR treatment for hereditary angioedema (HAE).
Phase 3 HAELO met its primary and all key secondary endpoints, showing most patients were free from HAE attacks and ongoing therapy during the six-month primary period. Intellia expects to complete the BLA in the second half of 2026 and, if approved, plans a commercial launch in the first half of 2027. Lonvo-z holds RMAT designation and participated in the FDA CMC pilot to help expedite review.
Positive
- Phase 3 HAELO met primary and all key secondary endpoints
- Initiated rolling BLA submission to FDA for lonvo-z
- RMAT designation granted for lonvo-z, enabling expedited pathways
- Participated in FDA CMC Development and Readiness Pilot to coordinate review
- Company plans commercial launch H1 2027 if approved
Negative
- BLA completion and regulatory acceptance are anticipated, not yet finalized
- Approval is conditional; FDA acceptance and priority review remain uncertain
- Planned timelines depend on FDA review milestones and could shift
News Market Reaction – NTLA
In the Apr 27 session, NTLA declined 4.33%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.0% during that session. Argus tracked a trough of -30.2% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 03 | Inducement equity grants | Neutral | +1.3% | New employee RSU inducement awards under the 2024 Inducement Plan. |
| Mar 06 | Inducement equity grants | Neutral | +3.4% | Restricted stock unit grants to new employees under Nasdaq Rule 5635(c)(4). |
| Mar 03 | Clinical data update | Positive | -11.9% | Longer-term lonvo-z data in HAE showing durable attack reduction and control. |
| Mar 02 | Clinical hold lifted | Positive | +12.1% | FDA lifted clinical hold on MAGNITUDE Phase 3 ATTR-CM trial with safety measures. |
| Feb 26 | Earnings and pipeline | Positive | +6.4% | Q4/FY 2025 results with cash of $605.1M and detailed lonvo-z timelines. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past clinically focused announcements for lonvo-z and other programs sometimes saw sharp, non-linear reactions, including one notable selloff on positive clinical data.
Over the last few months, Intellia reported routine inducement equity grants in March–April 2026 with modest positive price reactions. Key clinical updates included the FDA lifting a clinical hold on the MAGNITUDE Phase 3 ATTR-CM trial, which coincided with a 12.05% gain, and longer-term positive clinical data for lonvo-z at AAAAI 2026, after which shares fell 11.88%. The latest BLA-initiating news for lonvo-z extends this pattern of major clinical milestones eliciting volatile, sometimes counterintuitive trading.
Key Terms
biologics license application regulatory
in vivo medical
crispr gene editing medical
regenerative medicine advanced therapy regulatory
rmat regulatory
chemistry, manufacturing, and controls regulatory
cmc regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expect to complete BLA submission in second half of 2026; anticipate launch in first half of 2027, if approved
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it has initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of lonvo-z (formerly known as NTLA-2002) for hereditary angioedema (HAE). Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradykinin levels.
Intellia also separately announced positive topline data today from the Phase 3 HAELO clinical trial of lonvo-z in HAE. The trial met its primary and all key secondary endpoints, demonstrating that a one-time dose of lonvo-z led to freedom from both HAE attacks and the use of ongoing therapy for most patients during the six-month primary observation period.
“If approved, lonvo-z will become the world’s first in vivo CRISPR-based gene editing therapy,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “The promising results from HAELO reinforce our conviction that lonvo-z could revolutionize how HAE is treated for many patients, with the potential to free most of them from both attacks and the need for ongoing therapy with just one dose. We look forward to our continued engagement with the FDA as we seek to ease many of the burdens for people living with HAE.”
Pursuant to the Regenerative Medicine Advanced Therapy (RMAT) designation that the FDA granted to lonvo-z for the treatment of HAE, a rolling BLA allows Intellia to submit portions of the BLA on an ongoing basis and provides the FDA with an opportunity to expedite its review. In addition to the RMAT program, Intellia participated in the FDA’s Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot. This program allows sponsors to discuss their CMC product development strategies and goals with FDA review staff and address their questions. The increased communication is intended to help sponsors complete CMC activities to expedite their drug development programs to support application submission and earlier patient access.
Intellia anticipates completing its BLA submission in the second half of 2026. If the filing is accepted by the FDA, the agency is expected to determine if it will grant a priority review and provide a target action date to complete its evaluation. If approved, Intellia plans to launch lonvo-z commercially in the first half of 2027.
About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose. Lonvo-z has received five notable regulatory designations: Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its program for lonvoguran ziclumeran or “lonvo-z” (also known as NTLA-2002) for the treatment of hereditary angioedema (“HAE”), including its plan to complete the submission of a biologics license application (“BLA”) for lonvo-z in the second half of 2026, its expectations regarding review and approval of that BLA, including the potential for expedited review, its expectations regarding a planned U.S. launch of lonvo-z in first half of 2027, and the possibility that lonvo-z to revolutionize how HAE is treated for many patients with the potential to free most from both attacks and the need for ongoing therapy with just one dose.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z, including risks related to the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicommunications.com
